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Epigenetic Changes of EGFR Have an Important Role
in BRAF Inhibitor–Resistant Cutaneous Melanomas
Jinhua Wang1, Sharon K. Huang1, Diego M. Marzese1, Sandy C. Hsu2, Neal P. Kawas1, Kelly K. Chong1,
Georgina V. Long3, Alexander M. Menzies3, Richard A. Scolyer3,4, Sivan Izraely5, Orit Sagi-Assif5,
Isaac P. Witz5 and Dave S.B. Hoon1,2
BRAF mutations are frequent in cutaneous melanomas, and BRAF inhibitors (BRAFi) have shown remarkable
clinical efficacy in BRAF mutant melanoma patients. However, acquired drug resistance can occur rapidly and
tumor(s) often progresses thereafter. Various mechanisms of BRAFi resistance have recently been described;
however, the mechanism of resistance remains controversial. In this study, we developed BRAFi-resistant
melanoma cell lines and found that metastasis-related epithelial to mesenchymal transition properties of BRAFi-
resistant cells were enhanced significantly. Upregulation of EGFR was observed in BRAFi-resistant cell lines and
patient tumors because of demethylation of EGFR regulatory DNA elements. EGFR induced PI3K/AKT pathway
activation in BRAFi-resistant cells through epigenetic regulation. Treatment of EGFR inhibitor was effective in
BRAFi-resistant melanoma cell lines. The study demonstrates that EGFR epigenetic activation has important
implications in BRAFi resistance in melanoma.
Journal of Investigative Dermatology (2015) 135, 532–541; doi:10.1038/jid.2014.418; published online 30 October 2014
INTRODUCTION
Despite recent major advances in therapies, the prognosis for
melanoma patients with advanced stage disease remains very
poor (Gopal et al., 2010; Siegel et al., 2012). Approximately
50% of melanomas harbor an activating BRAF V600 mutation
(BRAFmt; Davies et al., 2002; Long et al., 2011; Jakob et al.,
2012), an oncogene known to have an important role in the
proliferation and progression of melanoma cells through
activation of the rapidly accelerated fibrosarcoma (RAF)/
mitogen-activated protein kinase (MAPK)/ERK kinase (MEK)/
extracellular signal–regulated kinase (ERK) cell signaling path-
way (Gopal et al., 2010). FDA approved BRAF inhibitors
(BRAFi) such as vemurafenib (PLX4032, Roche, San Francisco,
CA) and recently dabrafenib (GSK2118436, GlaxoSmithKline,
London, UK) were used to inhibit the RAF/MEK/ERK signaling
pathway by targeting BRAFmt (Flaherty et al., 2012; Lito et al.,
2012). Clinical studies have shown that stage IV BRAFmt
melanoma patients respond rapidly to BRAFi therapies with
high response rates (Flaherty et al., 2010; Chapman et al.,
2011; Falchook et al., 2012; Hauschild et al., 2012; Long
et al., 2012). However, a majority of patients eventually
develop resistance.
Recently, studies have attempted to identify mechanisms
and changes associated with BRAFi resistance. Studies have
shown that other signal transduction pathways, such as the
IGF1R/PI3K/AKT pathway (Villanueva et al., 2010) and the
MAPK pathway (Johannessen et al., 2010), were hyper-
activated when the RAS/RAF/MAPK/ERK pathway was blocked
by BRAFi. Studies have also demonstrated that overexpression
of proteins such as CRAF, N-RAS, cyclin D1, FGF Receptor 3,
EGFR, and platelet-derived growth factor receptor b contribute
to melanoma BRAFi resistance (Montagut et al., 2008; Smalley
et al., 2008; Nazarian et al., 2010; Shi et al., 2011; Yadav
et al., 2012; Girotti et al., 2013). Mutation of PTEN (Paraiso
et al., 2011) and gatekeeper residue in BRAF (Whittaker et al.,
2010) have also been associated with acquired BRAFi
resistance in melanoma. An increase in RTK-ligand levels,
through autocrine tumor-cell production, paracrine contribu-
tion from tumor stroma, or systemic sources, could confer
resistance to BRAFi (Wilson et al., 2012). BRAFi resistance
have been reported to be developed through NRAS mutations
(Nazarian et al., 2010), BRAFV600E mutation amplification
(Shi et al., 2012), and BRAFV600E alternative splice variants
(Poulikakos et al., 2011). However, the acquired mechanisms
of BRAFi resistance remains elusive in melanoma patients.
In this study, we found that EGFR expression was signifi-
cantly upregulated in BRAFi-resistant melanoma cells and
tumor tissues and that the EGFR/PI3K/AKT pathway is hyper-
activated in BRAFi-resistant melanoma cells. Our results
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suggested that, in melanoma, BRAFi resistance is caused by
enhanced EGFR expression through epigenetic regulation and
that activation of the EGFR/PI3K/AKT pathway contributes to
melanoma progression.
RESULTS
Epithelial to mesenchymal transition characterizes melanoma
resistance to BRAFi
Melanoma, a tumor of neuroectodermal origin, can display
epithelial to mesenchymal transition (EMT), which is a com-
plex process associated with invasion and metastasis of
various types of solid tumors (Kudo-Saito et al., 2009; Weiss
et al., 2012; Craene and Berx, 2013). We developed several
BRAFi melanoma cells (see Materials and Methods) and
compared their phenotype with respective parental cells.
BRAFi-resistant melanoma cells were more elongated and
fibroblast-like in shape compared with respective parental
cells and resembled mesenchymal cells (Figure 1a; Supple-
mentary Figure 1 online). To determine whether expression of
known mesenchymal protein markers was changed, we
performed immunoblotting on paired cells. The expression
of vimentin, fibronectin, a-smooth muscle actin, and
N-cadherin was upregulated in BRAFi-resistant cells
(Figure 1b). This confirmed that development of BRAFi
resistance is associated with an EMT phenotype.
Resistant cells have aggressive growth
We characterized BRAFi-resistant melanoma cells and showed
that migration and invasion were higher in BRAFi-resistant
cells than in respective parental cells (Figures 1c and d;
Supplementary Figures 2 and 3 online). The soft agar colony
formation assay was performed to investigate the cell’s ability
to grow unattached to a surface suspended in agar. The 3D
matrigel assay was used to monitor invasive potential of cells.
To compare growth and invasive potential of parental and
resistant cells, we performed the soft agar colony formation
assay and 3D matrigel gel culture. Our results showed that
BRAFi-resistant cells grew faster compared with respective
parental cells in soft agar and 3D matrigel culture (Figures 1e
and f). Furthermore, quantification of colony formation was
shown in Supplementary Figure 4A online, and morphology of
M14 to M14R and M219 to M219R in 3D matrigel growth
medium (days 1 and 12) was shown for comparison in
Supplementary Figure 4B online and Figure 1f, respectively.
Analysis of cell growth also confirmed faster growth of BRAFi-
resistant cells compared with respective parental cells in 2D
adherent cell culture (Supplementary Figures 5A and B
online). Combining together, this suggested that resistant cells
have more aggressive growth compared with parental cells.
Cyclin D1 activity is related to cell cycle regulation and cell
proliferation (Ray et al., 2010; Choi et al., 2012). Immunoblot
analysis demonstrated that expression of cyclin D1 was
approximately twofold higher in BRAFi-resistant cells than in
respective parental cells (Supplementary Figures 5C and D
online). These results supported the aggressive growth
properties of BRAFi-resistant cells. Upregulated expression of
cyclin D1 accelerates G(1)-phase progression in the cell cycle
through the RAS/RAF/MEK/ERK pathway (Cai et al., 2013).
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Figure 1. Epithelial to mesenchymal transition (EMT) of BRAF inhibitor (BRAFi)-resistant cells. Proliferation, migration, and invasion of BRAFi-resistant cells.
(a) BRAFi-resistant melanoma cells (M14R and M219R) were more elongated and fibroblast-like in shape compared with respective parental cells (M14 and
M219). Bar ¼ 100mm. (b) Immunoblots of EMT protein markers (vimentin, fibronectin, N-cadherin, and alpha-smooth actin (SMA)). (c) Migration of melanoma
parental cells (M14 and M219) and BRAFi-resistant cells (M14R and M219R). Bar¼ 100mm. (d) Invasion of parental cells and BRAFi-resistant cells. Bar¼ 100mm.
(e) Cell growth in soft agar. (f) Cell growth in 3D matrigel. Migration and invasion were higher in BRAFi-resistant cells than in respective parental cells, and BRAF-
resistant cells grew faster compared with parental cells in soft agar and 3D matrigel. Bar¼100mm.
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Tumorigenicity of parental versus BRAFi-resistant melanoma
xenografts
To assess the tumorigenic properties of parental versus BRAFi-
resistant cells in vivo, 1106 cells from M219, and M219R
cell lines were inoculated subdermally into the thigh of male
nude-BALB/c mice (6 mice per cell line). BRAFi-resistant cells
had significantly higher tumorigenicity and faster growth
compared with respective parental cells (Supplementary
Figure 6 online). The xenograft study demonstrated the aggres-
sive growth properties of BRAFi-resistant cells (M219R)
in vivo, supporting the respective analysis of the in vitro cell
line studies (Supplementary Figure 5A online). This in vivo
xenograft analysis is one paired parental and resistant cell line.
EGFR expression is enhanced in BRAFi-resistant melanoma cells
Gene expression profiling by gene expression microarray
(Affymetrix array) analysis was performed on M14, M14R,
M219, and M219R cell lines to identify major significant
changes in BRAFi cells compared with respective parental
cells. EGFR mRNA expression level was identified 5.51-fold
higher in M14R than in M14 cells and 2.76-fold higher in
M219R than in M219 cells (Figure 2a, left). RNA-sequence
analysis of total RNA from M14 and M14R cells verified
higher(6.23-fold) RNA expression for EGFR in M14R cells than
in M14 cells (Supplementary Figure 7 online). Quantitative
real-time reverse-transcriptase–PCR analysis further confirmed
higher expression of mRNA EGFR in M14R(3.85-fold higher)
and M219R(5.62-fold higher) cells than in respective parental
cells (Figure 2a, right).
To determine whether protein expression of EGFR was
enhanced in BRAFi-resistant cell lines, we assessed EGFR
expression by immunoblotting and flow cytometry. As shown
in Figures 2b and c, EGFR expression was significantly higher
in BRAFi-resistant cells than in respective parental cells.
EGFR expression is enhanced in BRAFi-resistant melanoma
metastases
We assessed the EGFR expression level by immunohistochem-
istry in American Joint Committee on Cancer stage III and IV
metastatic melanomas using a melanoma tissue microarray
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Figure 2. EGFR expression in metastatic melanoma cells (panels a–c) and metastatic melanoma tissues (panels d–f). (a) EGFR mRNA expression in parental (M14
and M219) and BRAF inhibitor (BRAFi)-resistant (M14R and M219R) cells assessed by gene expression microarray (left) and quantitative real-time reverse-transcriptase–
PCR (right) analyses. (b) Immunoblot of EGFR expression in cells. (c) Flow cytometric analysis of EGFR expression in cells. (d) Representative immunohistochemistry
(IHC) stain of EGFR in a metastatic tumor specimen obtained before (A) and after (B) treatment with BRAFi. In picture b, melanoma has higher EGFR expression
compared with normal cells in tissue. Bar¼ 100mm. (e) Intensity of EGFR IHC staining in melanoma tumors obtained from patients before and after treatment with
BRAFi (three pre-treatment patients were not available). (f) EGFR methylation array (left) and EGFR methylation-specific PCR (right). Error bars¼ SD (*P o0.05).
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(TMA) that was annotated with long-term clinical follow-up
data (non BRAFi treatment; Nguyen et al., 2010). American
Joint Committee on Cancer stage III and IV melanomas
generally had low levels of EGFR expression independent of
BRAFmt presence (Supplementary Figure 8 online).
To determine whether EGFR expression was enhanced in
BRAFi-resistant melanomas, we immunostained melanoma
tumor specimens obtained from 15 patients before and after
BRAFi treatment with dabrafenib (13 patients) or vemurafenib
(2 patients; Figure 2d and Supplementary Figure 9 online).
Analysis of staining intensity showed that EGFR expression
was higher in BRAFi-resistant tumors (Figure 2e). To confirm
these results, we compared EGFR expression in autologous
pairs of BRAFmt melanoma specimens obtained from 12
different patients before and after treatment with BRAFi
(Supplementary Figure 10 online). EGFR expression post
treatment was significantly higher in BRAFi-resistant recurrent
tumor.
EGFR gene hypomethylation in BRAF-resistant cells
As EGFR was demonstrated to be significantly activated in
BRAFi-resistant cells, we investigated its expression regulation.
Methylation profiling with a HumanMethylation450 BeadChip
(Illumina, San Diego, CA) analysis was carried out to deter-
mine whether EGFR was epigenetically regulated by CpG site
methylation status. The methylation level of the EGFR
promoter region was 14.9-fold lower in M14R cells than in
M14 cells and 16.4-fold lower in M219R cells than in M219
cells (Figure 2f, left). Methylation-specific PCR confirmed
lower EGFR methylation in M14R and M219R cells than in
respective parental cells (Figure 2f, right). To verify whether
hypermethylation of EGFR affects its expression, M14 and
M219 cells were treated with a 5-azacytidine demethylation
agent and assessed for EGFR protein expression by immuno-
blotting. EGFR expression was enhanced in cells treated by
5-azacytidine (Figure 3d; Supplementary Figure 11 online).
These results supported that EGFR expression is regulated by
the CpG methylation status in the promoter region.
EGFR expression is regulated by the methylation status of EGFR
enhancers
Genome-wide DNA methylation and transcriptomic integra-
tive analyses were carried out to further determine whether
enhanced EGFR expression in BRAFi-resistant cells was
regulated by changes in CpG site methylation. The data from
bead chip methylation array were assessed to establish a linear
regression and were used to estimate Pearson’s correlation
coefficient (r) between the methylation level and the EGFR
expression level. The analysis included a 65 kb upstream
region and a 180 kb downstream region, both measured from
the transcription start site of the EGFR gene (Figure 3a). The
targeted genomic region analysis included the promoter,
50UTR, 30UTR, and gene coding regions. The promoter region
of EGFR gene presents two CpG islands with respective shores
and shelves that were also targeted by this analysis. One
enhancer region was located upstream of the transcription
start site, represented by probe number 4, and the other was
located downstream of the transcription start site in the first
intron of the gene, represented by probe number 51
(Figure 3b). The regions that showed significant correlation
between DNA methylation and the EGFR expression level
were located in enhancer elements (r; Po0.05; Figure 3c). The
comparative methylation analysis of parental and BRAFi-
resistant cells demonstrated a consistent hypomethylation in
BRAFi-resistant cells in CpG sites located in the upstream
and downstream enhancers. EGFR downstream enhancer
methylation status was verified by methylation-specific PCR.
Supplementary Figure 12 online demonstrated that methyla-
tion of EGFR downstream enhancers was much lower in
M14R and M219R cells than in respective parental M14 and
M219 cells. This strongly suggested that EGFR expression is
regulated by methylation status of EGFR enhancers in the
BRAFi-resistant melanoma cells.
EGFR expression is associated with cell resistance to BRAFi
The effect of EGFR inhibitor (EGFRi) on BRAFi-resistant
melanoma cells was evaluated by treating M14 and M14R
cells by BRAFi with or without EGFRi. M14 cells were
sensitive to BRAFi but not EGFRi, whereas M14R were not
sensitive to BRAFi but sensitive to EGFRi (Figure 4a and
Supplementary Figures 13 and 14 online). Furthermore, M14R
cells were more sensitive to the combination of EGFRi and
BRAFi than to EGFRi alone.
To determine whether EGFR expression confers BRAFi
resistance to melanoma cells, we transfected M219 cells with
an EGFR expression plasmid and selected stable clones with
high EGFR expression (Figure 4b, left). We also transfected
M14R with EGFR small interfering RNA to reduce expression
of EGFR (Figure 4b, right). M219 cells were more sensitive to
BRAFi than were M219-EGFR cells, and M14R-small interfer-
ing RNA cells were more sensitive to BRAFi than were M14R
(Figures 4c–e). Taken together, these results suggested that
EGFR activation was associated with BRAFi resistance in
melanoma cells.
EGFR/PI3K/AKT pathway is activated in BRAFi-resistant
melanoma cells
To determine whether growth of BRAFi-resistant cells depends
on EGFR activation, parental and resistant cells were cultured
in RPMI-1640 medium with or without EGF (20 ng ml–1).
There was no significant difference in cell growth of parental
and resistant cells cultured in medium without EGF
(Figure 5a). However, BRAFi-resistant cells grew faster com-
pared with parental cells when cultured in medium with EGF.
This suggested that growth of resistant cells was more
dependent on EGF compared with respective parent cells.
To further investigate EGFR activation in resistant mela-
noma cells, we employed Human Phospho-RTK array to
assess phosphorylation of receptor tyrosine kinase. EGFR
was more phosphorylated in resistant cells than in parental
cells (Figure 5b). This suggested that overexpression of EGFR
in resistant cells leads to enhanced tyrosine phosphorylation of
EGFR. To further confirm that EGFR activation in cells was
involved in acquired resistance to BRAFi, we performed
immunoblotting to evaluate phosphorylation of EGFR at
Tyr1068, which indicated kinase activation. Results
J Wang et al.
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demonstrated that phosphorylation of EGFR was significantly
enhanced (Figure 5c).
To examine whether EGFR was activated when the RAS/
RAf/MAPK/ERK pathway is blocked, M225 cells (high expres-
sion of EGFR, Figure 5d) were treated with the MEK inhibitor
AZD6244 or with BRAFi. After 24 hours, phosphorylated-
EGFR (Tyr1068) and p-AKT were significantly increased, EGFR
was also significantly increased, and p-ERK1/2 (p42/p44) was
significantly decreased in BRAFi-treated cells (Figure 5e and
Supplementary Figure 15 online). Expression of EGFR
was increased in BRAFi-treated cells. EGFR dimerization is
formed as the EGFR level increases. EGFR dimerization
stimulates its intrinsic intracellular protein tyrosine kinase
activity (autophosphorylation of EGFR), thereby the expression
of p-EGFR increases.
These results suggested that EGFR was activated when the
RAS/RAF/MAPK/ERK pathway was blocked.
To determine whether activation of EGFR leads to signaling
via the PI3K/AKT pathway, AKT phosphorylation was mon-
itored after treatment of M14 and M14R cells with EGF, alone
or in combination with the AKT inhibitor CCT128930(10mM).
AKT phosphorylation was significantly higher in M14R cells
and was inhibited by CCT128930 (Figure 5f).
To further confirm activation of the EGFR/PI3K/AKT path-
way, phosphorylation of p85, expression of PI3K components,
and downstream targets of the EGFR/PI3K/AKT pathway
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were assessed. Expression levels of p110 alpha, phos-
phorylated-p85 (Tyr458), p-AKT (473), and phosphorylated
4E-BP1 (downstream targets of the EGFR/PI3K/AKT pathway)
were higher in resistant cells than in parental cells (Figure 5g).
Taken together, these results suggested that the EGFR/PI3K/
AKT pathway is activated in BRAFi-resistant melanoma cells.
Combination of EGFRi and BRAFi overcomes acquired resistance
to BRAFi
To further confirm the role of EGFR in acquired resistance to
BRAFi, the effect of combining EGFRi and BRAFi on M14,
M14R, M219, and M219R cells grown in a 3D matrix tumor-
like microenvironment was assessed. M14R and M219R cells
were more sensitive to combined inhibitors than to either
single inhibitor. However, M14 and M219 cells (low EGFR
expression) were sensitive to BRAFi but not to EGFRi. The
photographs of the cells were taken at days 1 and 18 for
comparison (Figure 6a and Supplementary Figures 16–18
online). M14R and M219R cells (high EGFR expression) were
sensitive to the combined inhibitors, whereas M14 and M219
(low EGFR expression) were not sensitive to EGFRi. These
results indicated that activated EGFR is responsive to EGFRi in
BRAFi-resistant melanoma cells.
DISCUSSION
We present evidence that BRAFi-resistant melanoma cells
develop an EMT phenotype, and EGFR-mediated activation of
the PI3K-AKT pathway is induced as a consequence through
BRAFi resistance. Enhanced expression of EGFR in BRAFi-
resistant cells was due to epigenetic changes in EGFR activa-
tion. This epigenetic changes led to hyperactivity of the EGFR/
PI3K/AKT pathway. BRAFi-resistant melanoma cells were
sensitive to combined treatment with EGFRi and BRAFi.
Our results suggested that epigenetic changes of EGFR led
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to enhanced expression and played an important role in
BRAFi-resistant cells. The drug combination co-targeting
BRAFmt and EGFR-positive melanomas may provide an
effective alternative treatment strategy to improve durable
clinical responses.
BRAFi-resistant cells displayed a distinct EMT-like pheno-
type with spindle-shaped morphology as well as upregula-
tion of EMT markers. These morphological changes of
BRAFi-resistant cells confirmed previous results (Nazarian
et al., 2010). EMT has been associated with metastasis of
lung and pancreatic cancers that are resistant to treatment with
EGFR and AKT inhibitors (Byers et al., 2013; Marais et al.,
2013). Our results demonstrated that migration and invasion
of resistant cells were enhanced compared with parental cells.
The EMT phenotype and EGFR expression are known to be
closely related to cell migration and invasion (Zhang et al.,
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C6 (blue circle):p-HGFR; D17, D18 (green circle): p-EphR). Both pictures were exposured for 10 seconds. (c) Immunoblots of p-EGFR (Tyr1068) expression in
parental and resistant cells. (d) Expression of EGFR in three BRAF V600 mutation (BRAFmt)-bearing cell lines: M14, M219, and M225. (e) Immunoblots show that
MAPK/ERK kinase (MEK) inhibitor AZD6244 blocked MEK-mediated regulation of EGFR in BRAFmt cells. (f) Immunoblots of AKT and phosphorylated-AKT
expression in M14 and M14R cells exposed to EGF after a 1-hour treatment with AKT inhibitor. (g) Immunoblots show expression of components on the PI3K/AKT
pathway. Expression levels of p110 alpha, phosphorylated-p85 (Tyr458), p-AKT (473), and phosphorylated 4E-BP1 were higher in resistant cells than in parental
cells.
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Figure 6. Response of cells exposed to EGFR inhibitor (EGFRi) and BRAF inhibitor (BRAFi) in a 3D-tumor-like microenvironment. (a) M14 parental cells and
M14R resistant cells grown in a 3D-tumor-like microenvironment were treated with DMSO, BRAFi (SB590885), and/or EGFRi (erlotinib). Bar¼ 50mm. (b) Flow
diagram of EGFR/PI3K/AKT pathway activation in resistant cell lines treated by BRAFi. The EGFR/PI3K/AKT pathway was activated when the RAS/RAF/MEK/ERK
pathway was blocked by BRAFi.
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2012; Zhu et al., 2012). This may partially explain why
recurrent melanomas are more aggressive in BRAFi-resistant
melanoma patients. We believe these resistant cells revert to
an EMT-like phenotype with activation of the EGF signal
pathways. Melanoma is of embryonic neuroectoderm origin,
and during advanced stages may revert to its embryonic
ectoderm phenotype.
The modulation of EGFR transcription is a complex
mechanism that involves both genetic and epigenetic factors.
Our results suggested that the hypomethylation of two differ-
ent related promoters’ DNA elements significantly regulates
EGFR expression. Remarkably, these two regions are located
in the genomic enhancer elements. DNA enhancer elements
interact with protein complexes that regulate the transcrip-
tional rate of a gene or a group of genes. In breast cancer, the
mechanism involving the enhancers of EGFR gene was shown
to be related to anti-EGFR therapy response (McInerney et al.,
2001; Brandt et al., 2006).
In a study of colon cancer, investigators found that BRAFi
effect on BRAFmt tumors causes a rapid feedback activation of
EGFR, which supports cell growth (Prahallad et al., 2012).
EGFR-mediated reactivation of MAPK signaling allows
BRAFmt colorectal cancers to resist vemurafenib treatment
(Corcoran et al., 2012). Our results demonstrated that
expression of EGFR and phosphorylated-EGFR was increased
in BRAFi-resistant melanoma cells. Expression levels of P110a
and phosphorylated-p85 (Tyr458) in PI3K/AKT were
enhanced, whereas no significant enhancement on other
components of the MAPK/MEK/ERK pathway was observed.
We believe that the EGFR/PI3K/AKT pathway is activated
when the MAPK/MEK/ERK pathway is blocked by BRAFi.
EGFR IHC further confirmed that there was higher EGFR
expression in resistant melanoma tumors than in BRAFi pre-
treated melanoma patient tumors. EGFR-mediated reactivation
of PI3k/AKT signaling provided BRAFi-resistant melanoma
cells with an alternative mechanism to grow and progress.
Oncogene addiction is a phenomenon in which some
cancers that contain multiple genetic, epigenetic, and chro-
mosomal abnormalities remain dependent on (addicted to)
one or a few genes for both maintenance of the malignant
phenotype and cell survival, especially in drug-resistant
cancer cells (Weinstein, 2002; Torti and Trusolino, 2011;
Kuehl and Bergsagel, 2012). Our studies indicated that BRAFi-
resistant melanoma cells became ‘‘addicted to’’ EGFR
oncogenic activity as do EMT cells during tumor progres-
sion. Overexpression of EGFR rendered cells resistant to
BRAFi, whereas knockdown of EGFR rendered cells sensitive
to BRAFi. Expression of EGFR in BRAFi-resistant tumors was
increased, which also supported the findings that EGFR
rendered cells sensitive to BRAFi. These findings suggested
that EGFR has an important role in BRAFi resistance.
Development of resistance to tyrosine kinase inhibitors is a
common problem often associated with chronic treatment
with these receptor tyrosine kinase-targeted anticancer drugs
(Solit and Rosen, 2011). Drug combinations have recently
been employed widely to treat aggressive drug-resistant
melanomas (Kim et al., 2011; O’Day et al., 2013). We
demonstrated that growth of resistant cells was significantly
inhibited by a combination of BRAFi and EGFRi, whereby
growth was not affected by BRAFi alone. These findings
coincided with studies described in BRAFi treatment of
colon cancer (Prahallad et al., 2012). The EGFR/PI3K/AKT
pathway is activated when RAS/RAF/MEK/ERK is inhibited by
BRAFi. BRAFi-resistant cells are epigenetically activated to
overexpress EGFR and respond to EGF (Figure 6b).
This study is to demonstrate that EGFR conferred epigenetic
activation upon resistant development to BRAFi in vitro and
in vivo. Our MSP results showed that the methylation level of
EGFR in resistant cells was much lower than that in parental
cells. It is known that enhancer elements can have a major
regulation of gene expression and not strictly the methylation
status of the gene promoter region. Our results also showed
that there was consistent hypomethylation of EGFR in BRAFi-
resistant cells in CpG sites located in the enhancer region.
Taken together, our results suggested that the increase in EGFR
expression in resistant cells was due to epigenetic regulation
including hypomethylation of the promoter and enhancer
regions. We believe that epigenetic changes of EGFR have
an important role in aggressive tumor growth in BRAFi-
resistant cutaneous melanomas.
Our study sheds light on the molecular basis of resistance
and suggestive mechanisms of growth when BRAFi resistance
develops. The EGFR and EGF axis activation in melanomas
may be underestimated. It is known that primary melanoma
metastasizes to distant organ sites that are ectoderm in origin.
When invaded and damaged these organ sites release EGF for
repair and regrowth. As a consequence, the melanoma cells
bearing EGFR can take advantage of this microenvironment
damage repair to survive and continue to grow through this
process.
MATERIALS AND METHODS
Cell lines and tissues
The established human melanoma cell lines (M14, M219, and M225)
that contained BRAFV600Emt were used in the studies. Tumor tissues
from stage III/IV melanoma patients were obtained from Melanoma
Institute Australia, Sydney, Australia and JWCI (John Wayne Cancer
Institute, Santa Monica, CA) with written informed consent from each
patient under approved Human Research Ethics committee protocols.
Melanoma metastatic biopsies were taken from patients prior to
commencing BRAFi and after surgical resection when resistance and
progression occurred.
TMA
TMA were developed as previously described and were well
clinically annotated with 45 years follow-up (Camp et al., 2008;
Nguyen et al., 2010). AJCC Stage IV melanoma TMA included 268
distant organ metastases and 39 autologous stage III/LN metastases, as
well as 29 normal tissues from each respective organ (cancer-free).
BRAFi-resistant BRAFmt melanoma lines
To obtain melanoma-resistant cells, BRAFmt melanoma cells from
established cell lines M14, M219, and M225 of early passages were
cultured with gradually increasing concentration (0.1mM, 0.25mM,
0.5mM, 0.75mM, 1mM) of BRAFi(SB590885 in DMSO). SB590885, a
potent and highly selective inhibitor of BRAF kinase (Villanueva et al.,
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2010), was purchased from SYMANSIS NZ (Timaru, New Zealand).
Resistant melanoma cells were maintained in the continuous
treatment of 1mM of SB590885 for 3 months. These BRAFi-resistant
melanoma cell lines were designated as M14R, M219R, and M225R.
The resistant cells were maintained in the BRAFi drug treatment after
3 months. All the experiments were performed while cells were
maintained in the presence of the BRAFi drug.
RNA extraction and array-based gene expression analysis
Total RNA was extracted from melanoma-related specimens
using the RNeasy Mini Kit (QIAGEN, Valencia, CA). RNA
samples were analyzed by GeneChip Human Gene 1.0 ST Array
(Affymetrix, Santa Clara, CA) at the USC/CHLA Genome Core
Laboratory. Data were analyzed in Expression Console 1.1 software
(Affymetrix) using the core transcript set and employing the robust
multi-array average algorithm for background correction and normal-
ization of data.
RNA deep sequencing
Samples of high quality RNA (RINZ8.0) were used to create mRNA
libraries using the Illumina TruSeq RNA Sample Preparation Kit v2
(Illumina). The mRNA libraries were then sequenced on the Illumina
HiSeq 2500 high-throughput mode using the TruSeq SBS v3–HS 200
cycle kit (Illumina) according to standard procedures generating over
35 million 100-base pair paired-end reads per sample. Base calling
and demultiplexing were processed using CASAVA v1.8 (Illumina),
alignment was performed using TopHat2 (Baltimore, MD) (Kim et al.,
2013), and expression values were generated using Cufflinks (Roberts
et al., 2011).
Infinium HumanMethylation450K beadchip analysis
DNA was extracted from cell lines with the QIAamp DNA mini kit
(QIAGEN, Valencia, CA). Extracted DNA (1mg) was first treated with
sodium bisulfite and then recovered using the Zymo EZ DNA
methylation kit (Zymo Research, Irvine, CA), quantified and assessed
for quality according to the manufacturer’s specifications (Campan
et al., 2009). The Illumina HumanMethylation450K BeadChip
(Illumina) was used to assay the methylation status of 4450K CpG
sites across the genome (Marzese et al., 2014). Data were processed
at the USC High Performance Computing Center (HPCC) using a
dedicated, Linux-based, high performance computational cluster. The
methylation level was reported as a beta-value (b¼ intensity of the
methylated allele/intensity of the unmethylated alleleþ intensity of
the methylated allele), which was calculated using the signal intensity
value for each CpG site.
Biostatistical analysis
The results are presented as mean±SD of samples measured in
triplicate and repeated three times. Student’s t-test was used to
calculate differences between the various study groups. Significant
difference was considered at Po0.05.
Additional materials and methods information is available in
Supplementary Material online.
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